In order to assess the effect of APOC3 alleles on lipid levels and risk of dyslipidemia, and to check potential confounders or interactions, the contribution of treatment- and time-dependent factors were collectively evaluated (Table 3). This evidence concerns the gene APOC3 and metabolic syndrome.